Paclitaxel Polymeric Micelles for Injection

1. Indications and Usage
Advanced Breast Cancer:
Treatment of patients with advanced breast cancer, either as a monotherapy or in combination with other chemotherapeutic agents.
Non-Small Cell Lung Cancer (NSCLC):
Treatment of patients with locally advanced or metastatic non-small cell lung cancer.
Note: Indications may vary by region (e.g., initially approved in Korea).
2. Dosage and Administration
Route of Administration:
For Intravenous (IV) Infusion ONLY.
Recommended Dosage:
Monotherapy: Typically 135 mg/m² or 200 mg/m² (dose depends on manufacturer guidelines and regional approval) administered every 3 weeks.
Combination Therapy: Dose adjustments are required when used with platinum-based drugs (e.g., Carboplatin).
Critical Administration Instructions:
Reconstitution: The drug must be reconstituted with 5% Dextrose Injection (D5W) or 0.9% Sodium Chloride Injection (depending on specific regional labeling, typically D5W is standard for stability).
Dilution: Dilute the reconstituted solution in a polyvinyl chloride (PVC) or non-PVC infusion bag containing 5% Dextrose Injection.
Infusion Rate: Administer over 60 minutes.
Filtration: Use an in-line filter (pore size 0.22 µm or 0.45 µm) during administration.
3. Mechanism of Action
Nanotechnology-Based Delivery:
The drug consists of hydrophobic paclitaxel molecules entrapped within the hydrophobic core of amphiphilic block copolymer micelles (typically Polyethylene Glycol-Block-Poly(Methoxypropyl) Carbamate).
Microtubule Stabilization:
Once released in the circulation, paclitaxel binds to tubulin, inhibiting microtubule depolymerization and arresting cell division at the G2/M phase.
Enhanced Permeability: The nanoscale size of the micelles allows for passive targeting of tumor tissues via the Enhanced Permeability and Retention (EPR) effect.
4. Safety and Warnings
Hypersensitivity Reactions:
Although the incidence is significantly lower than conventional Cremophor EL-based paclitaxel, hypersensitivity reactions can still occur.
Action: Monitor patients closely during infusion. Pre-medication with corticosteroids and antihistamines may be considered based on physician judgment.
Myelosuppression:
Neutropenia is the most common dose-limiting toxicity. Regular monitoring of blood counts is essential.
Peripheral Neuropathy:
Sensory neuropathy (numbness, tingling) is common. Dose reduction is required if severe symptoms occur.
Contraindications:
History of serious hypersensitivity to paclitaxel or the polymer excipients.
Baseline neutrophil count < 1,500/mm³.
5.Adverse Reactions and Clinical Research
Most Common Adverse Reactions:
Neutropenia, leukopenia, anemia, sensation of coldness, alopecia, nausea, vomiting, and peripheral neuropathy.
Clinical Research Highlights:
Efficacy: Clinical trials (e.g., in NSCLC) have shown that Genexol-PM is as effective as standard paclitaxel in terms of response rates and survival.
Safety Advantage: Studies demonstrated a significantly lower incidence of severe hypersensitivity reactions compared to solvent-based paclitaxel. However, neutropenia remains a significant adverse event.
6.Drug Interactions
CYP2C8 and CYP3A4:
Paclitaxel is metabolized by CYP2C8 and CYP3A4. Caution is advised when co-administering with potent inhibitors (e.g., gemfibrozil, ketoconazole).
Carboplatin:
When used in combination, the clearance of paclitaxel may be reduced by carboplatin, potentially requiring dose adjustments.
7.Pharmaceutical Information
Chemical Composition:
Active Ingredient: Paclitaxel.
Excipient: Methoxypropyl carbamate-block-polyethylene glycol (MPCE-b-PEG).
Appearance: White to yellowish lyophilized powder or cake.
Packaging: Single-use vial (e.g., 50 mg or 100 mg).
Storage: Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F).